Webcast CME

Series Activities

Series Menu

Clinical Management of Myeloid Malignancies:
The Coming of Age of Targeted Therapies

Clinical Management of Myeloid Malignancies Cases

Print this Content

Release date: March 6, 2020
Expiration date: March 6, 2022

Estimated Time of Completion: 30 minutes

Description

Cleveland Clinic and Aplastic Anemia & MDS International Foundation present Myeloproliferative Neoplasms, part of the Clinical Management of Myeloid Malignancies: The Coming of Age of Targeted Therapies online series, will provide an in-depth review of myeloproliferative neoplasms, risk stratification, prognostic implications, and treatment options.

Learning Objectives

  1. Formulate appropriate evaluation and management strategies for patients with myeloid malignancies.

Target Audience

This educational activity is designed for an international audience including medical oncologists/hematologists, clinical and translational researchers, and other physicians and allied health care professionals treating patients with MDS and other bone marrow failure diseases. In addition, members of patient advocacy groups will benefit from this program.

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Cleveland Clinic Foundation Center for Continuing Education and Aplastic Anemia & MDS International Foundation. The Cleveland Clinic Foundation Center for Continuing Education is accredited by the ACCME to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

Activity Director and Faculty

Activity Director

Betty Hamilton, MD    
Department of Hematology and Medical Oncology    
Taussig Cancer Institute    
Cleveland Clinic    
Cleveland, OH

Faculty

Angela Fleischman, MD, PhD
Assistant Professor of Medicine    
Chao Family Comprehensive Cancer Center   
University of California, Irvine   
Irvine, CA

Lukasz Gondek, MD, PhD
Assistant Professor of Oncology   
Sidney Kimmel Comprehensive Cancer Center   
Division of Hematologic Malignancies   
Department of Oncology   
Johns Hopkins University School of Medicine   
Baltimore, MD

Alan List, MD
Tampa, FL

Uwe Platzbecker, MD
Director, Medical Clinic I - Hematology and Cell Therapy   
University Hospital Leipzig   
Leipzig, Germany

Phillip Scheinberg, MD
Head, Division of Hematology                                              
Hospital A Beneficência Portuguesa                                     
São Paulo, Brazil

Eytan Stein, MD
Memorial Sloan Kettering Cancer Center   
New York, NY

CME Disclaimer

The information in this educational activity is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition. The viewpoints expressed in this CME activity are those of the authors/faculty. They do not represent an endorsement by The Cleveland Clinic Foundation. In no event will The Cleveland Clinic Foundation be liable for any decision made or action taken in reliance upon the information provided through this CME activity.

Disclosures

In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias. 

The following faculty have indicated that they may have a relationship, which in the context of their presentation(s), could be perceived as a potential conflict of interest:

Uwe Platzbecker, MD Celgene Corporation; Jazz Pharmaceuticals Consulting; Teaching and Speaking
Geron Consulting; Other activities from which remuneration is received or expected: Research
Janssen; Takeda Consulting
Novartis Oncology  Teaching and Speaking 
Phillip Scheinberg, MD Novartis Consulting; Membership on advisory committee or review panels; Teaching and Speaking
Eytan Stein, MD Agios Pharmaceuticals Consulting
Auron Therapeutics Ownership interest (stock, stock options)
Astellas Pharma US, Inc.; Bioline Pharmaceuticals; Celgene Corporation; Daiichi Sankyo, Inc.; Epizyme; Genentech; Novartis;
PTC Therapeutics, Inc.; Syros Pharmaceuticals, Inc.
Membership on advisory committee or review panels

The following faculty have indicated they have no relationship which, in the context of their presentation(s), could be perceived as a potential conflict of interest:

Angela Fleischman, MD
Lukasz Gondek, MD
Betty Hamilton, MD
Alan List, MD

 

Acknowledgement

The Cleveland Clinic Foundation Center for Continuing Education acknowledges educational grants for partial support of the Internet Enduring activity from:
Celgene Corporation
Geron
Jazz Pharmaceuticals
Onconova
Takeda

 


This CME activity was produced by the Cleveland Clinic Foundation Center for Continuing Education, Cleveland Clinic’s Taussig Cancer Institute and Aplastic Anemia & MDS International Foundation.